SCHEMBL4063153

SCHEMBL4063153

O=C(NCc1ccc(CO)cc1)c1c(Cl)cncc1Cl

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
EPHX2 P34913 2/20 0.47
HSD17B10 Q99714 1/20 0.45
NHERF1 O14745 2/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPC1 O15118 1/20 0.44
ITGB1 P05556 1/20 0.44
ITGA4 P13612 1/20 0.44
ALDH2 P05091 5/20 0.43
SCN2A Q99250 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4066669 0.88 HPGD (0.48) TSHRCYP1A2CYP2C9HPGDCYP2C19
SCHEMBL4058800 0.85 TSHR (0.45) TSHRCYP1A2CYP2C9HPGDCYP2C19
SCHEMBL4061966 0.84 EPHX2 (0.50) TSHRCYP1A2CYP2C9HPGDCYP2C19
SCHEMBL4063160 0.81 ITGB1 (0.64) ITGB1ITGA4
SCHEMBL27529312 0.81 TSHR (0.50) TSHRCYP1A2CYP2C9HPGDCYP2C19
SCHEMBL10107746 0.76 ALDH2 (0.77) TSHRHPGDHSD17B10MEN1KMT2A
SCHEMBL26922366 0.73 ALDH2 (0.57) HPGDMEN1KMT2AALDH2
SCHEMBL9505080 0.72 ALDH2 (0.59) TSHRCYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3918322 0.71 TSHR (0.76) TSHRHPGDEPHX2MEN1KMT2A
SCHEMBL30745582 0.70 HDAC3 (0.49) CYP1A2CYP2C19LMNAITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317443-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2009-01-14 EP disclosed
US-20080090846-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS GENZYME CORPORATION 2008-04-17 US disclosed
US-7312234-B2 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2007-12-25 US disclosed
US-20050026942-A1 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2005-02-03 US disclosed
US-6835731-B2 Viricides; antiinflammatory agents; antiallergens; antiarthritic agents ANORMED, INC. (CA) 2004-12-28 US disclosed
CN-1458929-A Chemokine receptor binding heterocyclic compounds ANORMED INC (CA) 2003-11-26 CN disclosed
EP-1317443-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 EP disclosed
US-20020147192-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2002-10-10 US disclosed
WO-2002022599-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147192-A1 Chemokine receptor binding heterocyclic compounds CCR2, CXCR3, ACKR3 TSHR 668/4885CYP1A2 2986/4885CYP2C9 2254/4885
US-20080090846-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS CCR2, CXCR3, ACKR3 TSHR 668/4885CYP1A2 2986/4885CYP2C9 2254/4885
US-20050026942-A1 Chemokine receptor binding heterocyclic compounds CCR2, CXCR3, ACKR3 TSHR 668/4885CYP1A2 2986/4885CYP2C9 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.